Teva- Pharmaceutical Industries Ltd. - ADR

Teva- Pharmaceutical Industries Ltd. - ADR

TEVA

Market Cap$15.64B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Teva- Pharmaceutical Industries Ltd. - ADRTeva- Pharmaceutical Industries Ltd. - ADR-9.4--18%13.4

Earnings Call Q4 2024

January 29, 2025 - AI Summary

Strong Revenue Growth: Teva reported robust revenue of $16.5 billion for 2024, marking a 9% increase year-over-year (YOY). This growth was driven primarily by innovative products AUSTEDO (34% growth), AJOVY (18% growth), and UZEDY (exceeding $100 million in revenue by reaching $117 million), showcasing effective execution on their growth strategy.
Innovative Product Forecasts: For 2025, Teva aims for significant contributions from its key products, projecting AUSTEDO revenues to be between $1.9 billion to $2 billion, AJOVY over $600 million, and UZEDY $160 million. This indicates confidence in continuing momentum in their innovative drug portfolio.
Earnings and EBITDA Expectations: The non-GAAP earnings per share (EPS) is forecasted at $2.35 to $2.65 for 2025, with non-GAAP adjusted EBITDA expected between $4.5 billion and $5 billion. However, this is not anticipated to significantly improve from 2024 levels, indicating potential operational challenges despite revenue growth.

Exclusive for Stockcircle Pro members

Sign upSign Up
$2.39

Current Fair Value

82% downside

Overvalued by 82% based on the discounted cash flow analysis.

Share Statistics

Market cap$15.64 Billion
Enterprise Value$30.42 Billion
Dividend Yield$0 (0%)
Earnings per Share$-1.45
Beta0.72
Outstanding Shares1,133,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-9.43
PEG1.46
Price to Sales0.95
Price to Book Ratio0.83
Enterprise Value to Revenue1.81
Enterprise Value to EBIT12.97
Enterprise Value to Net Income-31
Total Debt to Enterprise0.59
Debt to Equity3.36

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Teva- Pharmaceutical Industries Ltd.

CEO: Kaare Schultz